PONVORY®: an oral, once-daily, selective S1P1 therapy for relapsing MS in adults2-4



Proven efficacy and
safety profile2,5,6

The first and only oral disease-modifying therapy to show phase 3 head-to-head superiority vs another oral2,5,7-13

  • Superior reduction in relapses and lesions vs Aubagio®2,5§¶

No disability progression2

  • ~9 out of 10 patients taking PONVORY® did not experience disability progression over ~2 years (as measured by time to 3-month confirmed disability progression)#

Proven safety profile2,5,6

  • Proven safety profile vs Aubagio®; generally well-tolerated across multiple clinical studies (N≈1400)||


when needed2,8-10

One-week elimination2

  • Leaves the body naturally in 1 week, allowing for pregnancy 7 days after stopping PONVORY®

Fastest reversibility in the S1P class2,8-10

  • Lymphocyte counts returned to the normal range in 90% of patients within 1 week of stopping therapy, providing flexibility to pause therapy if needed (eg, infection, surgery)**


Onboarding steps
made convenient2,8-10

Unlike any other S1P modulator, PONVORY® has the unique combination of2,8-10:

  • No first dose monitoring for most patients††
  • No genetic testing
  • No known food restrictions
  • No known drug interactions with SSRIs

S1P = sphingosine-1-phosphate; SSRI = selective serotonin reuptake inhibitor.

*Collected in 3/22 and is subject to change. Within 2% of access being stated. This information does not provide advice or guarantee coverage or payment, is not intended to provide reimbursement advice, and is not intended to increase or maximize reimbursement by any payer. Legal requirements and plan information can be updated frequently. We strongly recommend contacting the plan for more information about current coverage, restrictions, or prerequisites that may apply. This may not represent 100% of formulary lives due to data limitations.1

The exact mechanism by which PONVORY® exerts therapeutic effects in MS is unknown but may involve reduction of lymphocyte migration into the central nervous system.2

In the phase 3, ~108-week OPTIMUM study, PONVORY® was shown to reduce the average number of relapses per year and the average number of new gadolinium-enhancing (GdE) T1 and new or enlarging T2 lesions.2,5

§Over the study period of ~108 weeks, lesions measured included the number of new GdE T1 lesions and new or enlarging T2 lesions (without double counting).2

The lesions endpoint is based on the cumulative number of combined unique active lesions as a prespecified secondary endpoint.2,5

#There was no statistically significant difference between the PONVORY® and Aubagio® groups.2

||Includes the OPTIMUM study and the phase 2, 6-month, placebo-controlled study and the uncontrolled extension studies.2

**As seen in pharmacokinetic-pharmacodynamic assessments.2

††First dose, 4-hour monitoring is recommended for patients with sinus bradycardia (heart rate <55 beats per minute), first- or second-degree atrioventricular block (Mobitz type I), or a history of myocardial infarction or heart failure occurring >6 months prior to treatment initiation and in stable condition.2